Back to top
more

Corbus Pharmaceuticals (CRBP)

(Delayed Data from NSDQ)

$56.66 USD

56.66
255,419

-2.41 (-4.08%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $55.92 -0.74 (-1.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Tops Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 49.71%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -2250.00% and -91.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

What's in Store for Sorrento (SRNE) This Earnings Season?

Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

Corbus Pharmaceuticals (CRBP) to Report Q1 Results: Wall Street Expects Earnings Growth

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for BioDelivery (BDSI) This Earnings Season?

Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

What's in the Cards for AEterna (AEZS) This Earnings Season?

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

All You Need to Know About Corbus Pharmaceuticals (CRBP) Rating Upgrade to Buy

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals (CRBP) Stock Moves -1.23%: What You Should Know

Corbus Pharmaceuticals (CRBP) closed the most recent trading day at $7.23, moving -1.23% from the previous trading session.

Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know

Corbus Pharmaceuticals (CRBP) closed at $7.18 in the latest trading session, marking a -0.97% move from the prior day.

Is Corbus Pharmaceuticals Holdings (CRBP) Stock Outpacing Its Medical Peers This Year?

Is (CRBP) Outperforming Other Medical Stocks This Year?

Corbus Pharmaceuticals (CRBP) Upgraded to Strong Buy: Here's Why

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Misses Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -36.36% and -3.02%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.

Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates

Pacira (PCRX) impresses investors with both earnings and revenue beat in the fourth quarter.

Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher

Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%

Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.

Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Corbus Pharmaceuticals (CRBP) closed at $7.64, marking a -0.52% move from the previous day.

Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

Corbus Pharmaceuticals (CRBP) needs investors to pay close attention to the stock based on moves in the options market lately.